Aardvark therapeutics announces fda alignment on protocol amendment expanding phase 3 hero trial population for prader-willi syndrome

San diego, oct. 08, 2025 (globe newswire) -- aardvark therapeutics, inc. (aardvark) (nasdaq: aard), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announces alignment with the u.s. food and drug administration (fda) on a protocol amendment to the company's phase 3 hero trial of ard-101 for the treatment of hyperphagia associated with prader-willi syndrome (pws). the protocol amendment changes the minimum age of eligibility to participate in the trial from 13 to 10 years old.
AARD Ratings Summary
AARD Quant Ranking